Harry H Mellor (Harry Mellor)

Years Active: 2017-2022
Publications (10 Years): 5

University of Bristol

University of Bristol (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Bristol

United Kingdom

Graduate Dean for Life Sciences

University of Bristol

United Kingdom

Professor of Biochemistry :: Biochemistry

University of Bristol

United Kingdom

Reader :: Biochemistry

University of Bristol

United Kingdom

Welcome Trust University Award :: Biochemistry

University of Bristol

United Kingdom

Wellcome Trust Career Development Fellowship :: Biochemistry

Cancer Research UK LRI

United Kingdom

Postdoctoral Fellow

Penn State University

United States

Juvenile Diabetes Foundation International Personal Fellowship :: Cellular Molecular Physiology

Education History

University of Bristol

United Kingdom

PHD

University of Edinburgh

United Kingdom

BSC

Publications

Alba Lopez Rioja, Ashton Faulkner, Harry H Mellor
srGAP2 deactivates RhoA to control the duration of thrombin-mediated endothelial permeability. Vascular biology (Bristol, England) 4 (1) (2022)
Joseph W Hawkins, Madeleine C McNeill, Reza Ebrahimighaei, Harry H Mellor, Andrew C Newby, Mark Bond
Cyclic-AMP Increases Nuclear Actin Monomer Which Promotes Proteasomal Degradation of RelA/p65 Leading to Anti-Inflammatory Effects. Cells 11 (9) (2022)
Ashton Faulkner, Anita Tamiato, William Cathery, Andrea Rampin, Carlo Maria Caravaggi, Eva Jover, Steve Allen, Harry H Mellor, David Hauton, Lisa C Heather, Gaia Spinetti, Paolo Madeddu
Dimethyl-2-oxoglutarate improves redox balance and mitochondrial function in muscle pericytes of individuals with diabetes mellitus. Diabetologia 63 (10) (2020)
Asha L Bayliss, Ananthalakshmy Sundararaman, Camille Granet, Harry H Mellor
Raftlin is recruited by neuropilin-1 to the activated VEGFR2 complex to control proangiogenic signaling. Angiogenesis 23 (3) (2020)
Caroline M McKinnon, Harry H Mellor
The tumor suppressor RhoBTB1 controls Golgi integrity and breast cancer cell invasion through METTL7B. BMC cancer 17 (1) (2017)

Harry H Mellor.css-eqlu8i{font-size:small;padding-left:4px;} (Harry Mellor)